国际内分泌代谢杂志
國際內分泌代謝雜誌
국제내분비대사잡지
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2009年
1期
47-50
,共4页
促甲状腺激素垂体瘤%甲状腺毒症%诊断
促甲狀腺激素垂體瘤%甲狀腺毒癥%診斷
촉갑상선격소수체류%갑상선독증%진단
Thyrotropin-secreting pituitary tumors%Thyrotoxicosis%Diagnosis
对2例促甲状腺激素(TSH)垂体瘤患者的临床资料进行回顾性分析,并进行文献复习.2例患者都存在甲状腺毒症,均有甲状腺激素水平增高同时不伴TSH抑制,1例大腺瘤患者存在视野缺损.2例患者在确诊之前均误诊为原发性甲状腺功能亢进而接受抗甲状腺药物治疗4~7年,1例患者还曾行甲状腺大部切除术.确诊后大腺瘤患者行垂体瘤手术联合垂体放射治疗,另1例为微腺瘤患者,行垂体放射治疗.术后随访,2例患者的甲状腺功能亢进均较前改善.甲状腺毒症患者血清TSH水平不被抑制时应警惕TSH垂体瘤的存在,鞍区影像学检查可以进一步明确诊断,早期诊断和手术联合放射治疗可以取得较好的治疗效果.
對2例促甲狀腺激素(TSH)垂體瘤患者的臨床資料進行迴顧性分析,併進行文獻複習.2例患者都存在甲狀腺毒癥,均有甲狀腺激素水平增高同時不伴TSH抑製,1例大腺瘤患者存在視野缺損.2例患者在確診之前均誤診為原髮性甲狀腺功能亢進而接受抗甲狀腺藥物治療4~7年,1例患者還曾行甲狀腺大部切除術.確診後大腺瘤患者行垂體瘤手術聯閤垂體放射治療,另1例為微腺瘤患者,行垂體放射治療.術後隨訪,2例患者的甲狀腺功能亢進均較前改善.甲狀腺毒癥患者血清TSH水平不被抑製時應警惕TSH垂體瘤的存在,鞍區影像學檢查可以進一步明確診斷,早期診斷和手術聯閤放射治療可以取得較好的治療效果.
대2례촉갑상선격소(TSH)수체류환자적림상자료진행회고성분석,병진행문헌복습.2례환자도존재갑상선독증,균유갑상선격소수평증고동시불반TSH억제,1례대선류환자존재시야결손.2례환자재학진지전균오진위원발성갑상선공능항진이접수항갑상선약물치료4~7년,1례환자환증행갑상선대부절제술.학진후대선류환자행수체류수술연합수체방사치료,령1례위미선류환자,행수체방사치료.술후수방,2례환자적갑상선공능항진균교전개선.갑상선독증환자혈청TSH수평불피억제시응경척TSH수체류적존재,안구영상학검사가이진일보명학진단,조기진단화수술연합방사치료가이취득교호적치료효과.
Two patients with thyrotropin-secreting pituitary tumors were reported. And their clinical characteristics were analyzed retrospectively. Patients were presented with thyrotoxicosis and one had visual field defect. Hyperthyroidism was determined in these patients by means of elevated total or free thyroid hormone levels while serum TSH levels were not lower than detect limits. They were previously considered as suffering from primary hyperthyroidism and were treated with antithyroid drug for 4 to 7 years, one of them subsequently underwent subtotal thyroidectomy. MRI showed pituitary macroadenomas in 1 patients who underwent transsphenoidal adenomectomy and followed by radiotherapy, while microadenomas in the other patient who was given radiotherapy. Thyrotropin-secreting pituitary adenoma should be considered in patients with el-evated thyroid hormone and non-suppressed serum TSH level. Combined treatment with transsphenoidal adenomectomy and radiotherapy are the choice for thyrotropin-secreting pituitary tumors.